Clinical trials: Antiviral Agents
Chronic Hepatitis C
A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
A study to evaluate the safety and effect of treatment with experimental antiviral drugs in combination with peginterferon alpha-2a and ribavirin in people with hepatitis C virus who did not respond to treatment in a previous…
- Trial name
- NCT01609933
- Testing
- ABT-450/r, ABT-267, pegylated interferon alpha-2a (pegIFN)
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV-1-infection
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
Multicenter, parallel group, randomised, open label, study. Twenty-five clinical centers constituting the InAction network will participate the study.
- Trial name
- P25-INACTION (NCT04225325)
- Testing
- SYMTUZA, DESCOVY+DOLUTEGRAVIR, SYMTUZA+DOLUTEGRAVIR
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- ADRIANO LAZZARIN, MD
Hepatitis C
Clinical Performance Evaluation of DxN HCV Assay
The DxN Hepatitis C Virus (HCV) Assay is an in vitro diagnostic assay intended as an aid in the management of of HCV-infected individuals undergoing antiviral therapy.
- Trial name
- NCT03125408
- Testing
- HCV Assay
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Beckman Coulter, Inc.
Chronic Hepatitis C
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
The primary purpose of the study is to compare the safety and effectiveness of standard treatment for chronic hepatitis C using peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) to those same medications plus a dietary…
- Trial name
- NCT00571714
- Testing
- Peginterferon alpha-2a and ribavirin, Peginterferon alpha-2a , ribavirin and betaine
- Sponsor
- University of Nebraska
Symptomatic COVID-19 Infection Laboratory-Confirmed
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19).
- Trial name
- NCT04373044
- Testing
- Baricitinib, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Southern California
Hepatitis C, Chronic
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in…
- Trial name
- NCT01371578
- Testing
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
HIV-1-infection
Study of Novel Antiretrovirals in Participants With HIV-1
Master protocol: The goal of this master clinical trial study is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living…
- Trial name
- NCT05585307
- Testing
- Bavtavirine, B/F/TAF, Standard of Care (Substudy 01)
- Where
- 42 sites in United States, Dominican Republic and 1 more
- Volunteers
- 49 people
- Sponsor
- Gilead Sciences
Hepatitis B Virus
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
The purpose of this study is to evaluate the safety and immunotherapeutic activity of cemiplimab in participants with hepatitis B virus (HBV) on suppressive antiviral therapy.
- Trial name
- NCT04046107
- Testing
- Cemiplimab
- Where
- 8 sites in United States, Brazil and 2 more
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic, Liver Fibrosis
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Patients with chronic hepatitis C who did not respond to previous antiviral treatment develop liver fibrosis leading to cirrhosis.
- Trial name
- NCT00323804
- Testing
- Peginterferon alfa-2b, Ribavirin
- Where
- 45 sites in Belgium, France
- Volunteers
- 372 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Medication Adherence
Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs
People who Inject Drugs (PWIDs) constitute 60% of the approximately 5 million people in the United States infected with hepatitis C virus (HCV).
- Trial name
- NCT03127358
- Testing
- AiCure, AiCure with gamification
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Albert Einstein College of Medicine
Hepatitis C
Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy
The prevalence of HCV infection in Egypt is 14.7%. HCV is both a hepatotropic and a lymphotropic virus, it may exert a chronic stimulus on the immune system with both T and B lymphocyte alterations.
- Trial name
- NCT03226717
- Testing
- Antiviral agents
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatitis B, Chronic
Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B
It is estimated that 350-400 million people have chronic infection with hepatitis B virus (HBV) all over the world. In china, 93 million individuals suffer from this chronic condition.
- Trial name
- NCT02075294
- Testing
- Adefovir dipivoxil or Entecavir
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Ying-Jie Ji
COVID-19, Coronavirus Infection
Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)
Randomized, double-blind prospective trial to test the efficacy of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65…
- Conditions
- COVID-19, Coronavirus Infection, SARS CoV 2 Infection
- Trial name
- MOR2 (NCT05178173)
- Testing
- 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Pharmacological Action
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients
Evaluation of Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Egyptian Pediatric Patients With Chronic Hepatitis C Infection aged 10- 18 years old.
- Trial name
- NCT02985281
- Testing
- Sofosbuvir Oral Product, Ribavirin
- Where
- Egypt
- Volunteers
- 41 people
- Sponsor
- National Liver Institute, Egypt
Chronic Infection
Orange Juice Consumption in Patients With Hepatitis C
This study aimed to verify whether orange juice, source of citrus flavonoids and vitamin C, may contribute to the treatment of patients with chronic hepatitis C.
- Trial name
- NCT03026569
- Testing
- Orange juice (500 mL/d)
- Where
- Brazil
- Volunteers
- 43 people
- Sponsor
- São Paulo State University
Cytomegalovirus Retinitis, HIV Infections
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients
To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS patients experiencing their first episode of cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002039
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
Hepatitis B, Chronic
EFFicacy Optimization Research of Telbivudine Therapy
The purpose of this trial is to prove that the strategy of treatment adjustment at W24 according to virological response based on ROADMAP concept is better than standard of care strategy.
- Trial name
- EFFORT (NCT00962533)
- Testing
- telbivudine
- Where
- 24 sites in China
- Volunteers
- 606 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis C
Surveillance and Treatment of Prisoners With Hepatitis C
The purpose of the study is to assess how feasible it is to treat and prevent the transmission of Hepatitis C in the prison setting to achieve substantial reductions in the incidence and prevalence of Hepatitis C.
- Trial name
- SToP-C (NCT02064049)
- Testing
- Sofosbuvir/velpatasvir
- Where
- 4 sites in Australia
- Volunteers
- 3,692 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV Infections
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
- Trial name
- NCT03205917
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Hepatitis B, Chronic (CHB), Hepatitis B
Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
Chronic hepatitis B can develop into cirrhosis and liver cancer, which seriously endangers the life and health of people. In China, HBV is mainly transmitted from mother to child, showing the phenomenon of family clusters.
- Conditions
- Hepatitis B, Chronic (CHB), Hepatitis B, Hepatitis B Virus (HBV)
- Trial name
- NCT07079150
- Testing
- Peg IFN-α-2b
- Where
- 2 sites in China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.